Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.

Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, Lye WK, Putti TC, Dent R, Lim E, Thike AA, Tan PH, Iqbal J.

Front Immunol. 2018 May 30;9:1209. doi: 10.3389/fimmu.2018.01209. eCollection 2018.

2.

What is the role of immunotherapy in breast cancer?

Tan TJ, Chan JJ, Kamis S, Dent RA.

Chin Clin Oncol. 2018 Apr;7(2):13. doi: 10.21037/cco.2018.04.01.

3.

Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

Chan JJ, Tan TJY, Dent RA.

J Oncol Pract. 2018 May;14(5):281-289. doi: 10.1200/JOP.18.00034.

PMID:
29746805
4.

Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction.

Booth JN 3rd, Colantonio LD, Rosenson RS, Safford MM, Chen L, Kilgore ML, Brown TM, Taylor B, Dent R, Monda KL, Muntner P, Levitan EB.

J Am Heart Assoc. 2018 May 8;7(10). pii: e008462. doi: 10.1161/JAHA.117.008462.

5.

Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): prospective cohort study protocol.

Teo I, Singh R, Malhotra C, Ozdemir S, Dent RA, Kumarakulasinghe NB, Yeo WL, Cheung YB, Malhotra R, Kanesvaran R, Yee ACP, Chan N, Wu HY, Chin SM, Allyn HYM, Yang GM, Neo PSH, Nadkarni NV, Harding R, Finkelstein EA.

BMC Cancer. 2018 Apr 23;18(1):459. doi: 10.1186/s12885-018-4356-z.

6.
7.

ACSL5 genotype influence on fatty acid metabolism: a cellular, tissue, and whole-body study.

Rajkumar A, Liaghati A, Chan J, Lamothe G, Dent R, Doucet É, Rabasa-Lhoret R, Prud'homme D, Harper ME, Tesson F.

Metabolism. 2018 Jun;83:271-279. doi: 10.1016/j.metabol.2018.03.019. Epub 2018 Mar 29.

PMID:
29605434
8.

GreenCut protein CPLD49 of Chlamydomonas reinhardtii associates with thylakoid membranes and is required for cytochrome b6 f complex accumulation.

Wittkopp TM, Saroussi S, Yang W, Johnson X, Kim RG, Heinnickel ML, Russell JJ, Phuthong W, Dent RM, Broeckling CD, Peers G, Lohr M, Wollman FA, Niyogi KK, Grossman AR.

Plant J. 2018 Jun;94(6):1023-1037. doi: 10.1111/tpj.13915. Epub 2018 May 16.

PMID:
29602195
9.

Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.

Kramer B, Singh R, Wischusen J, Dent R, Rush A, Middlemiss S, Ching YW, Alexander IE, McCowage G.

Hum Gene Ther. 2018 Mar 23. doi: 10.1089/hum.2017.235. [Epub ahead of print]

PMID:
29385852
10.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I.

JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.

PMID:
29327055
11.

Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors.

Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, Chan A.

Psychooncology. 2018 Apr;27(4):1185-1192. doi: 10.1002/pon.4635. Epub 2018 Feb 1.

PMID:
29315963
12.

Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.

Chae JW, Chua PS, Ng T, Yeo AHL, Shwe M, Gan YX, Dorajoo S, Foo KM, Loh KW, Koo SL, Chay WY, Tan TJY, Beh SY, Lim EH, Lee GE, Dent R, Yap YS, Ng R, Ho HK, Chan A.

Breast Cancer Res Treat. 2018 Apr;168(3):713-721. doi: 10.1007/s10549-017-4640-7. Epub 2018 Jan 8.

PMID:
29313215
13.

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS.

Kim SB, Dent R, Wongchenko MJ, Singel SM, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Nov;18(11):e638. doi: 10.1016/S1470-2045(17)30785-4. Epub 2017 Oct 31. No abstract available.

PMID:
29208392
14.

Diet-resistant obesity is characterized by a distinct plasma proteomic signature and impaired muscle fiber metabolism.

Thrush AB, Antoun G, Nikpay M, Patten DA, DeVlugt C, Mauger JF, Beauchamp BL, Lau P, Reshke R, Doucet É, Imbeault P, Boushel R, Gibbings D, Hager J, Valsesia A, Slack RS, Al-Dirbashi OY, Dent R, McPherson R, Harper ME.

Int J Obes (Lond). 2018 Mar;42(3):353-362. doi: 10.1038/ijo.2017.286. Epub 2017 Nov 20.

15.

The role of feature-based discrimination in driving health disparities among Black Americans.

Dent RB, Hagiwara N, Stepanova EV, Green TL.

Ethn Health. 2017 Nov 6:1-16. doi: 10.1080/13557858.2017.1398314. [Epub ahead of print]

PMID:
29105509
16.

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.

Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D.

J Clin Lipidol. 2017 Nov - Dec;11(6):1448-1457. doi: 10.1016/j.jacl.2017.09.003. Epub 2017 Sep 22.

PMID:
29066265
17.

Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study.

Booth JN 3rd, Colantonio LD, Chen L, Rosenson RS, Monda KL, Safford MM, Kilgore ML, Brown TM, Taylor B, Dent R, Muntner P, Levitan EB.

Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10). pii: e003626. doi: 10.1161/CIRCOUTCOMES.117.003626.

PMID:
29021332
18.

Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.

Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.

J Am Heart Assoc. 2017 Oct 2;6(10). pii: e005367. doi: 10.1161/JAHA.116.005367. Review.

19.

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, Pruneri G, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F.

Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17.

20.

Is Type 2 Diabetes in Adults Associated With Impaired Capacity for Weight Loss?

Antoun G, Nikpay M, McPherson R, Harper ME, Dent R.

Can J Diabetes. 2018 Jun;42(3):313-316.e1. doi: 10.1016/j.jcjd.2017.06.010. Epub 2017 Aug 8. No abstract available.

PMID:
28800932
21.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8.

PMID:
28800861
22.

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.

Descamps OS, Fraass U, Dent R, März W, Gouni-Berthold I.

Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12979. Epub 2017 Jul 27. Review.

23.

A prospective study of docetaxel-associated pain syndrome.

Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D, Chiu L, Chow R, Wan BA, Pasetka M, Stinson J, Stacey E, Verma S, Lam H, Chow E, DeAngelis C.

Support Care Cancer. 2018 Jan;26(1):203-211. doi: 10.1007/s00520-017-3836-z. Epub 2017 Jul 22.

PMID:
28733699
24.

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.

Boccara F, Dent R, Ruilope L, Valensi P.

Adv Ther. 2017 Aug;34(8):1876-1896. doi: 10.1007/s12325-017-0586-8. Epub 2017 Jul 17. Review.

25.

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT.

JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.

PMID:
28715540
26.

Primary Care Physician Perspectives on Barriers to Statin Treatment.

Tanner RM, Safford MM, Monda KL, Taylor B, O'Beirne R, Morris M, Colantonio LD, Dent R, Muntner P, Rosenson RS.

Cardiovasc Drugs Ther. 2017 Jun;31(3):303-309. doi: 10.1007/s10557-017-6738-x.

PMID:
28710589
27.

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.

Pećin I, Hartgers ML, Hovingh GK, Dent R, Reiner Ž.

Eur J Prev Cardiol. 2017 Sep;24(13):1383-1401. doi: 10.1177/2047487317717346. Epub 2017 Jun 23.

29.

Novel Targeted Agents and Immunotherapy in Breast Cancer.

Mayer IA, Dent R, Tan T, Savas P, Loi S.

Am Soc Clin Oncol Educ Book. 2017;37:65-75. doi: 10.14694/EDBK_175631.

30.

Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries.

Rosenson RS, Gandra SR, McKendrick J, Dent R, Wieffer H, Cheng LI, Catapano AL, Oh P, Kees Hovingh G, Stroes ES.

Cardiovasc Drugs Ther. 2017 Apr;31(2):187-195. doi: 10.1007/s10557-017-6727-0.

31.

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.

Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS.

J Am Coll Cardiol. 2017 Mar 21;69(11):1386-1395. doi: 10.1016/j.jacc.2016.12.036.

32.

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.

Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators.

Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1.

33.

Evidence-based goals in LDL-C reduction.

Soran H, Dent R, Durrington P.

Clin Res Cardiol. 2017 Apr;106(4):237-248. doi: 10.1007/s00392-016-1069-7. Epub 2017 Jan 25. Review.

34.

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D.

Ann Oncol. 2017 Apr 1;28(4):754-760. doi: 10.1093/annonc/mdw665.

PMID:
27993816
35.

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.

Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH.

Circulation. 2017 Jan 24;135(4):338-351. doi: 10.1161/CIRCULATIONAHA.116.025080. Epub 2016 Dec 9.

36.

Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date.

McCormack T, Dent R, Blagden M.

Int J Clin Pract. 2016 Nov;70(11):886-897. doi: 10.1111/ijcp.12881. Epub 2016 Oct 14. Review.

37.

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.

Banach M, Stulc T, Dent R, Toth PP.

Int J Cardiol. 2016 Dec 15;225:184-196. doi: 10.1016/j.ijcard.2016.09.075. Epub 2016 Sep 26. Review.

PMID:
27728862
38.

Ten-year survival in women with primary stage IV breast cancer.

Eng LG, Dawood S, Sopik V, Haaland B, Tan PS, Bhoo-Pathy N, Warner E, Iqbal J, Narod SA, Dent R.

Breast Cancer Res Treat. 2016 Nov;160(1):145-152. Epub 2016 Sep 14.

PMID:
27628191
39.

Evolution of an atypical de-epoxidase for photoprotection in the green lineage.

Li Z, Peers G, Dent RM, Bai Y, Yang SY, Apel W, Leonelli L, Niyogi KK.

Nat Plants. 2016 Sep 12;2:16140. doi: 10.1038/nplants.2016.140.

40.

Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.

Rosenson RS, Jacobson TA, Preiss D, Djedjos SC, Dent R, Bridges I, Miller M.

Cardiovasc Drugs Ther. 2016 Oct;30(5):537. No abstract available.

PMID:
27497929
41.

Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.

Gouni-Berthold I, Descamps OS, Fraass U, Hartfield E, Allcott K, Dent R, März W.

Br J Clin Pharmacol. 2016 Dec;82(6):1412-1443. doi: 10.1111/bcp.13066. Epub 2016 Oct 4. Review.

42.

Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: a qualitative study.

Lee GE, Ow M, Lie D, Dent R.

BMC Womens Health. 2016 Jul 22;16:43. doi: 10.1186/s12905-016-0319-1.

43.

Guidelines for Burn Care Under Austere Conditions: Special Etiologies: Blast, Radiation, and Chemical Injuries.

Cancio LC, Sheridan RL, Dent R, Hjalmarson SG, Gardner E, Matherly AF, Bebarta VS, Palmieri T.

J Burn Care Res. 2017 Jan/Feb;38(1):e482-e496. doi: 10.1097/BCR.0000000000000367. No abstract available.

PMID:
27355658
44.

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.

Blom DJ, Dent R, Castro RC, Toth PP.

Vasc Health Risk Manag. 2016 May 9;12:185-97. doi: 10.2147/VHRM.S102564. eCollection 2016. Review.

45.

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.

Anders CK, Abramson V, Tan T, Dent R.

Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.14694/EDBK_159135. Review.

46.

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.

Rosenson RS, Jacobson TA, Preiss D, Djedjos CS, Dent R, Bridges I, Miller M.

Cardiovasc Drugs Ther. 2016 Jun;30(3):305-13. doi: 10.1007/s10557-016-6666-1. Erratum in: Cardiovasc Drugs Ther. 2016 Oct;30(5):537.

47.

Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.

Sutiman N, Lim JSL, Muerdter TE, Singh O, Cheung YB, Ng RCH, Yap YS, Wong NS, Ang PCS, Dent R, Schroth W, Schwab M, Khor CC, Chowbay B.

Clin Pharmacokinet. 2016 Oct;55(10):1239-1250. doi: 10.1007/s40262-016-0402-7.

PMID:
27098059
48.

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting.

Dent R, Joshi R, Stephen Djedjos C, Legg J, Elliott M, Geller M, Meyer D, Somaratne R, Recknor C, Weiss R.

Springerplus. 2016 Mar 9;5:300. doi: 10.1186/s40064-016-1892-3. eCollection 2016.

49.

Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.

Matsumoto H, Thike AA, Li H, Yeong J, Koo SL, Dent RA, Tan PH, Iqbal J.

Breast Cancer Res Treat. 2016 Apr;156(2):237-47. doi: 10.1007/s10549-016-3743-x. Epub 2016 Mar 9.

PMID:
26960711
50.

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.

Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E.

Cardiovasc Drugs Ther. 2016 Jun;30(3):297-304. doi: 10.1007/s10557-016-6655-4.

PMID:
26936841

Supplemental Content

Support Center